Pemetrexed
- Generic Name
- Pemetrexed
- Brand Names
- Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21N5O6
- CAS Number
- 137281-23-3
- Unique Ingredient Identifier
- 04Q9AIZ7NO
- Background
Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small cell lung cancer has also been investigated. Pemetrexed was first approved by the FDA in February 4, 2004.
- Indication
Pemetrexed is indicated for the treatment of the following conditions:
Non-squamous non-small cell lung cancer (NSCLC)
Malignant pleural mesothelioma
- Associated Conditions
- Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma
- Associated Therapies
- Monotherapy
Randomized Comparative Study of Erlotinib and Pemetrexed in the Maintenance Treatment of Advanced Lung Cancer Patients.
- Conditions
- Interventions
- First Posted Date
- 2018-03-09
- Last Posted Date
- 2020-03-05
- Lead Sponsor
- Hikma Pharmaceuticals LLC
- Target Recruit Count
- 9
- Registration Number
- NCT03460678
- Locations
- 🇯🇴
King Hussein Cancer Center (KHCC), Amman, Jordan
🇱🇧American University of Beirut Medical Center, Beirut, Lebanon
A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)
- Conditions
- Interventions
- First Posted Date
- 2018-03-07
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 453
- Registration Number
- NCT03456063
- Locations
- 🇺🇸
USC Norris Cancer Center, Los Angeles, California, United States
🇺🇸Arizona Oncology, Tucson, Arizona, United States
🇺🇸The Center for Cancer Prevention and Treatment at St.Joseph Hospital of Orange, Orange, California, United States
A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-03-07
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 257
- Registration Number
- NCT03456076
- Locations
- 🇷🇺
Pavlov First Saint Petersburg State Medical University, St. Petersburg, Sankt Petersburg, Russian Federation
🇷🇺Scientific Research Oncology Institute named after N.N. Petrov; Oncology, St. Petersburg, Sankt Petersburg, Russian Federation
🇷🇺GUZ Regional clinical hospital # 1, Krasnodar, Russian Federation
Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung Cancer
- First Posted Date
- 2018-02-14
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 54
- Registration Number
- NCT03432598
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Beijing Chest Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳Jiangsu Province Hospital, Nanjing, Jiangsu, China
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
- Conditions
- Interventions
- First Posted Date
- 2018-02-07
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 797
- Registration Number
- NCT03425643
- Locations
- 🇺🇸
UPMC Hillman Cancer Centers ( Site 0041), Pittsburgh, Pennsylvania, United States
🇺🇸PPG-Oncology ( Site 0043), Fort Wayne, Indiana, United States
🇺🇸Ingalls Memorial Hospital ( Site 0044), Harvey, Illinois, United States
The EPIC Trial The Elderly Patient Individualized Chemotherapy Trial
- First Posted Date
- 2018-01-17
- Last Posted Date
- 2020-11-04
- Lead Sponsor
- University of Turin, Italy
- Target Recruit Count
- 567
- Registration Number
- NCT03402048
- Locations
- 🇮🇹
Ospedale di Faenza, Faenza, Ravenna, Italy
🇮🇹AUSL Rimini-Oncologia Medica Cattolica, Cattolica, Rimini, Italy
🇮🇹AOU Santa Croce e Carle, Cuneo, Italy
Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001)
- First Posted Date
- 2018-01-11
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 184
- Registration Number
- NCT03396445
- Locations
- 🇺🇸
Florida Cancer Specialists ( Site 0002), Sarasota, Florida, United States
🇮🇱Soroka Medical Center-Oncology ( Site 0012), Be'er Sheva, Israel
🇺🇸The West Clinic, P.C. ( Site 0021), Germantown, Tennessee, United States
A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer
- First Posted Date
- 2017-12-21
- Last Posted Date
- 2021-02-26
- Lead Sponsor
- BioNTech US Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT03380871
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-11-21
- Last Posted Date
- 2019-06-13
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 2
- Registration Number
- NCT03348904
- Locations
- 🇺🇸
Pacific Cancer Medical Center, Inc, Anaheim, California, United States
🇺🇸Cancer Center of Kansas, Wichita, Kansas, United States
A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)
- Conditions
- Interventions
- Drug: AtezolizumabDrug: DocetaxelDrug: RO6958688Drug: CPI-444Drug: LinagliptinDrug: Sacituzumab GovitecanDrug: BevacizumabDrug: CamonsertibDrug: CobimetinibDrug: IpatasertibDrug: PemetrexedDrug: EvolocumabDrug: TiragolumabOther: RadiationDrug: TocilizumabDrug: CarboplatinDrug: GemcitabineDrug: XL092
- First Posted Date
- 2017-11-09
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 314
- Registration Number
- NCT03337698
- Locations
- 🇨🇳
Taipei Veterans General Hospital, Taipei City, Taiwan
🇪🇸Hospital Clinico Universitario de Valencia, Valencia, Spain
🇨🇳National Cheng Kung University Hospital; Gasterointestinal, Tainan City, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.